VTGN on Nasdaq

Vistagen Therapeutics, Inc.

American pharmaceutical preparations company based in South San Francisco. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

$1.3MRevenue, fiscal 20262
-$69.7MNet income, fiscal 20262

Compare with IGC Pharma, Inc., SciSparc or NRX Pharmaceuticals, Inc., or pick any stock.

  • TickerVTGN on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSouth San Francisco, California1
  • Incorporated inNV3
  • Business address343 Allerton Avenue, South San Francisco, Ca 940803
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a late clinical-stage therapeutics company focused on developing and potentially commercializing new medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. Each of the five clinical-stage intranasal pherine product candidates in our neuroscience pipeline has a novel neurocircuitry-focused proposed mechanism of action (MOA) and at least one positive clinical study in its targeted patient population. Leveraging our deep understanding of nose-to-brain neurocircuitry, we have designed our intranasal pherine product candidates are designed to rapidly, specifically and selectively bind to peripheral receptors in human nasal chemosensory neurons and rapidly activate neurocircuits believed to regulate brain areas, without requiring systemic absorption or uptake into the brain to achieve de…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-5683.7%Operating margin2
-5491.3%Net margin2
161.1%Revenue growth, 20262
-196.2%Return on equity2

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Research and development100¢$55.0M
  • Income tax0¢$7.0K

Out of $1.3M in revenue.2 The company lost money this year.

Financial statements

Revenue5672$1.3M in 2026
-$500.0K0$500.0K$1.0M$1.5M2020: $0$020202021: $1.1M$1.1M20212022: $1.1M$1.1M2022+2%2023: -$227.0K-$227.0K20232024: $1.1M$1.1M20242025: $486.0K$486.0K2025−54%2026: $1.3M$1.3M2026+161%
Operating income85961072-$72.1M in 2026+194% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$24.6M-$24.6M20192020: -$20.8M-$20.8M2020−15%2021: -$17.9M-$17.9M2021−14%2022: -$47.8M-$47.8M2022+166%2023: -$59.3M-$59.3M2023+24%2024: -$33.0M-$33.0M2024−44%2025: -$56.0M-$56.0M2025+70%2026: -$72.1M-$72.1M2026+29%
Net income85961072-$69.7M in 2026+183% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$24.6M-$24.6M20192020: -$20.8M-$20.8M2020−16%2021: -$17.9M-$17.9M2021−14%2022: -$47.8M-$47.8M2022+166%2023: -$59.2M-$59.2M2023+24%2024: -$29.4M-$29.4M2024−50%2025: -$51.4M-$51.4M2025+75%2026: -$69.7M-$69.7M2026+36%

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2026-03-312025-03-31
Total revenues$1.3M$486.0K
Research and development$55.0M$39.4M
General and administrative$18.4M$17.1M
Total operating expenses$73.4M$56.5M
Loss from operations-$72.1M-$56.0M
Interest income, net$2.4M$4.6M
Other income, net$7.0K$5.0K
Loss before income taxes-$69.7M-$51.4M
Income taxes-$7.0K-$7.0K
Net loss-$69.7M-$51.4M
Unrealized gain (loss) on marketable securities-$7.0K$5.0K
Comprehensive loss-$69.7M-$51.4M
Loss per share, basic (in dollars per share)-$1.83-$1.67
Loss per share, diluted (in dollars per share)-$1.83-$1.67
Weighted average common shares outstanding, basic (in shares)38.1M shares30.9M shares
Weighted average common shares outstanding, diluted (in shares)38.1M shares30.9M shares

Compare Vistagen Therapeutics, Inc. with another company

Leadership

Who has led Vistagen Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Shawn Singh2011–now

President

  1. Stephanie Jones2009–2011
  2. Shawn Singh2025–now

Chief financial officer

  1. A. Franklin Rice2011
  2. Jerrold Duane Dotson2011–2023
  3. Nick B. Tressler2025–now

Chief operating officer

  1. A. Franklin Rice2011
  2. Joshua S. Prince2023–now
2010201520202025
Board members and other officers (22)

Former names

  • Excaliber Enterprises, Ltd.Sep 11, 2007 to Jun 8, 20113

Timeline

  1. May 25, 2011New chief executive Shawn Singh becomes CEO14

Filings

310 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 117 major events, 92 insider forms, 51 large holders, 1 private raises, 29 other. The latest 20:

  1. Oct 9, 20268-K EDGAR
  2. Sep 25, 20268-K EDGAR
  3. Sep 24, 20268-K EDGAR
  4. Sep 22, 20268-K EDGAR
  5. Sep 11, 20268-K EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 14, 202610-Q EDGAR
  8. Aug 14, 20268-K EDGAR
  9. Aug 14, 2026SCHEDULE 13G/A EDGAR
  10. Aug 14, 2026SCHEDULE 13G/A EDGAR
  11. Aug 6, 20268-K EDGAR
  12. Aug 5, 20268-K EDGAR
  13. Jul 31, 20264 EDGAR
  14. Jul 31, 20263 EDGAR
  15. Jul 31, 2026DEFA14A EDGAR
  16. Jul 31, 2026DEF 14A EDGAR
  17. Jul 31, 20268-K EDGAR
  18. Jul 2, 20264 EDGAR
  19. Jul 2, 20264 EDGAR
  20. Jul 2, 20264 EDGAR

The 310 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 4 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 7, 2023COMMODORE CAPITAL LP10% ownerBuy775,756$23.15$18.0MForm 4
Aug 18, 2022GIN JERRY BDirectorBuy200,000$0.18$36.0KForm 4
Aug 17, 2022Adler Reid G.Chief Legal OfficerBuy300,000$0.17$51.0KForm 4
Aug 17, 2022Singh ShawnPresident and CEOBuy600,000$0.17$102.0KForm 4
Jul 12, 2022VHCP Management II, LLC10% ownerSale60,000$0.89$53.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 2, 2023Filed a private offering of equity Form D: $2.8 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 49. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Commodore Capital LP2,788,620$630.2K0.0%New
Vanguard Capital Management LLC1,574,200$355.8K0.0%No change
Two Sigma Investments, LP847,992$191.6K0.0%+378,373
Renaissance Technologies LLC730,500$165.1K0.0%+439,200
Ikarian Capital, LLC519,077$117.3K0.0%No change
AdvisorShares Investments LLC438,643$99.1K0.0%+161,533
Luminus Management LLC403,115$91.1K0.1%+7,062
Geode Capital Management, LLC365,002$82.5K0.0%−88,389
ADAR1 Capital Management, LLC351,141$79.4K0.0%−400,000
BlackRock, Inc.345,432$78.1K0.0%−103,075
Group One Trading LLC304,385$68.8K0.0%+284,510
Verdad Advisers, LP293,343$66.3K0.1%+108,405
Vanguard Fiduciary Trust Co217,700$49.2K0.0%No change
Jane Street Group, LLC164,827$37.3K0.0%−107,984
Boothbay Fund Management, LLC134,571$30.4K0.0%No change
State Street Corp121,114$27.4K0.0%No change
XTX Topco Ltd118,380$26.8K0.0%−34,469
Northern Trust Corp80,823$18.3K0.0%+8,168
Stempoint Capital LP616,749$17.3K0.0%−616,749
Citadel Advisors LLC68,839$15.6K0.0%New
UBS Group AG57,830$13.1K0.0%−20,906
Osaic Holdings, Inc.43,888$10.1K0.0%+39,755
Confluence Wealth Services, Inc.32,610$7.4K0.0%New
Scientech Research LLC30,283$6.8K0.0%New
StoneX Group Inc.10,840$6.6K0.0%−4,358

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57